Hoverink Biotechnologies (HVBH) S-1 2 Nov 17 2017 Q3 IPO registration Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2017shares
Document Information [Line Items]
Entity Registrant Name	Hoverink Biotechnologies, Inc.
Entity Central Index Key	1,586,494
Trading Symbol	hvbh
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)	36,772,000
Document Type	S1
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
ASSETS
Cash and cash equivalents	$ 0	$ 0	$ 0
Total Current assets		50
Notes receivable	50
Total assets	50	50
LIABILITIES AND STOCKHOLDERS' DEFICIT
Bank overdraft			3
Accounts payable	105,843	118,515	24,290
Accrued liabilities	31,178
Note payable-related parties	154,653	154,653	120,214
Total Current Liabilities	291,674	273,169	144,507
Note payable-related parties	115,060
Total Liabilities	406,734	273,169	144,507
Shareholders' Deficit
Additional paid in capital	1,407	1,407	1,407
Discount on Common Stock	(1,387)	(1,387)	(1,387)
Common stock $0.0001 par value, 100,000,000 shares authorized, 13,872,000 issued and outstanding at December 31, 2016 and 2015, and 36,772,000 issued and outstanding at September 31, 2017	3,677	1,387	1,387
Accumulated deficit	(410,381)	(274,526)	(145,914)
Total Shareholders' deficit	(406,684)	(273,119)	(144,507)
Total Liabilities and Shareholders Deficit	$ 50	$ 50

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000	100,000,000
Common stock, shares issued (in shares)	36,772,000	13,872,000	13,872,000
Common stock, shares outstanding (in shares)	36,772,000	13,872,000	13,872,000

Statements of Operation

Statements of Operation - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue
Services
Total Revenue
Cost of Goods sold
Gross profit
Operating Expenses
General and administrative	132,856	122,659	142,602
Travel and entertainment		5,952	1,905
Office occupancy	3,000
Total Operating Expenses	135,856	128,611	144,507
Income from operations	(135,856)	(128,611)	(144,507)
Other income (expense)
Interest expense
Other income
Total other income (expense)
Net Income	$ (135,856)	$ (128,611)	$ (144,507)
Basic and diluted net loss per share (in dollars per share)	$ 0	$ (0.01)	$ (0.01)
Basic and diluted weighted average common shares outstanding used in computing net loss per share (in shares)	36,772,000	13,872,000	13,872,000

Statements of Shareholders' Equ

Statements of Shareholders' Equity - USD ($)	Common Stock [Member]	AOCI Attributable to Parent [Member]	Discount on Common Stock [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2014	20,000,000
Balance at Dec. 31, 2014	$ 2,000		$ (2,000)
Redemption of shares (in shares)	(19,500,000)
Redemption of shares	$ (1,950)		1,950
Issuance of founder shares (in shares)	13,266,000
Issuance of founder shares	$ 1,326		(1,326)
Shares issued for services (in shares)	106,000
Shares issued for services	$ 11		(11)
Shareholder Contribution		1,407			1,407
Net income				(145,914)	(144,507)
Balance (in shares) at Dec. 31, 2015	13,872,000
Balance at Dec. 31, 2015	$ 1,387	1,407	(1,387)	(145,914)	(144,507)
Net income				(128,611)	(128,611)
Balance (in shares) at Dec. 31, 2016	13,872,000
Balance at Dec. 31, 2016	$ 1,387	1,407	(1,387)	(274,526)	(273,119)
Shares issued for services (in shares)	22,900,000
Shares issued for services	$ 2,290			(2,290)
Net income				(133,565)	(135,856)
Balance (in shares) at Sep. 30, 2017	36,772,000
Balance at Sep. 30, 2017	$ 3,677	$ 1,407	$ (1,387)	$ (410,381)	$ (406,684)

Statements of Cash Flow

Statements of Cash Flow - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ (135,856)	$ (128,611)	$ (144,507)
Adjustments to reconcile net income to net cash used by operating activities:
Stock issued for services	2,290		11
Changes in operating assets and liabilities:
Notes receivable		(50)
Accounts payable	(12,672)	94,225	24,290
Accrued liabilities	31,178
Net cash provided by (used in) operating activities	(115,060)	(34,436)	(120,206)
Investing Activities:
Net cash used in investing activites
Financing Activities:
Notes Payable	115,060	34,439	120,214
Common stock Redemmed			(2,000)
Common stock issued as founder shares			1,376
Discount on common stock			613
Net cash provided by (used in) financing activities	115,060	34,439	120,204
NET INCREASE (DECREASE) IN CASH	0	3	(3)
Cash at beginning of period		(3)
Cash at end of period	0		(3)
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for taxes

Note 1 - Nature of Operations a

Note 1 - Nature of Operations and Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION We are an innovative preclinical biopharmaceutical company committed to the discovery development, manufacturing and commercializing LADAVRU® and biosimilars. LADAVRU is a proprietary opioid alternative which is deliverable as an IV injectable, OR solid preparation containing; Citric Acid, Mannitol and Dronabinol, a cannabinoid designated chemically as ( 6aR 6a,7,8,10a 6,6,9 3 6Hdibenzo[b,d]pyran 1 1 1 2 6aR 6a,7,8,10a 6,6,9 3 6H 1 Corporate Information On September 8th, 2017, ’s issued and outstanding shares by written consent in lieu of a meeting, filed a Certificate of Change (the “ Certificate of Change ”) with the Secretary of State of Delaware. As a result of the Certificate of Change, the Company will be changing its name to “Hoverink Biotechnologies, Inc.”, effective as of September 11, 2017. In February 2015, ’s name from Sky Run Acquisition Corporation to Hoverink Biotechnologies, Inc. Prior to this the company was a shell as defined in Rule 405. We were incorporated in Delaware in July 2013 1801 24th 90067:866 443 4666 Our website address is in beta at https://hoverinkbiotech.yolasite.com/. We do not not ‘ Going Concern The Company ’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not $274,526 145,914 December 31, 2016 2015, $410,381 September 30, 2017. In order to continue as a going concern, the Company needs to develop a reliable source of revenues, and achieve a profitable level of operations. During the nine September 30, 2017 December 31, 2016 2015, To fund operations for the next twelve $10,000,000 If the Company is unable to obtain adequate capital, it could be forced to cease operations. Accordingly, the accompanying financial statements are accounted for as if the Company is a going concern and do not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10Q X. not not Cash The Company considers highly liquid financial instruments purchased with a maturity of three September 30, 2017 December 31, 2016 2015, no From time to time, we may $250,000 no not not Segmented Reporting FASB ASC 280, Comprehensive Loss “Reporting Comprehensive Income,” establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at September 30, 2017, no not Use of Estimates and Assumptions In preparing financial statements in conformity with generally accepted accounting principles in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheet and revenue and expenses in the statement of operations. The accounting estimates that require our significant, difficult, and subjective judgments include: ● the assessment of recoverability of long lived assets; ● the valuation of derivative instruments; and ● the valuation and recognition of share-based compensation. Actual results may may Fair Value of Financial Instruments The Company follows guidance for accounting for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements on a recurring basis. Additionally, the Company adopted guidance for fair value measurement related to nonfinancial items that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis. The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 three • Level I inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2 • Level 3 The level in the fair value hierarchy within which a fair measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety. Development Stage Company The Company is a development stage company, as defined in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915. ’s planned principal operations have not Management plans to seek funding from its shareholders and other qualified investors to pursue its business plan. Revenue recognition According to ASC 605, Advertising We expense advertising costs as incurred. During the Year ended December 31, 2016 2015 no no Loss per Common Share The basic earnings (loss) per share is calculated by dividing the Company ’s net income available to common shareholders by the weighted average number of common shares during the period. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items in the Company. Income Taxes The Company utilizes the asset and liability method of accounting for income taxes. The asset and liability method requires that the current or deferred tax consequences of all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not not In July 2006, not fifty no December 31 2016 2015 September 30, 2017. The Company follows the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax balances and tax loss carry- forwards. Deferred tax assets and liabilities are measured using enacted or substantially enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment or substantive enactment. Stock-based Compensation The Company follows ASC 718 10, 718 10 No. 123, No. 25, 718 10 in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized. The Company has not not September 30, 2017 not nor no Concentration of Credit Risk The Company maintains its cash with a major financial institution located in the United States of America which it believes to be credit worthy. Balances are insured by the Federal Deposit Insurance Corporation up to $250,000. Risks and Uncertainties The Company has a limited operating history and has not In addition, the Company will compete with many companies that currently have extensive and well-funded projects, marketing and sales operations as well as extensive human capital. Our company may may Recent Accounting Pronouncements In June 2014, 2014 10, 915 2014 10 2014 10 December 15, 2014, 2014 10 September 30, 2014, no 915. The FASB issued ASU 2014 15 August 27, 2014, statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one December 15, 2016, In November 2014, 2014 16, 815 2014 16 December 15, 2015. No. 2014 16 In August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 first 2018. 2016 15 not 2016 15 In May 2017, 2017 09, Compensation - Stock Compensation (Topic 718 718. 2017 09 June 30, 2019 not The Company has implemented all new accounting pronouncements that are in effect and that may not

Note 4 - Notes Payable - Relate

Note 4 - Notes Payable - Related Party	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 6 – RELATED PARTY TRANSACTIONS On March 31 2015 $150,000 March 31, 2019, no On January 21, 2016, $35,000 rom a consultant to the company. The note is due in 2019 no $35,000. On August 6, 2017 second $119,713. one no
Notes Payable [Member]
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 4 – NOTES PAYABLE-RELATED PARTY On January 4, 2015, $150,000 2019 no $119,653. On January 21, 2016, $35,000 2019 no $35,000. On August 11, 2017, $115,000 2019 no $115,000.

Note 5 - Capital Stock

Note 5 - Capital Stock	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 5 – CAPITAL STOCK The Company ’s capitalization is 100,000,000 $0.0001 No On February 15, 2015, 19,500,000 $0.0001 $1,950. On February 16, 2015, 13,372,000 On September 2, 2017, 1,000,000 On September 22, 2017, 21,900,000

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 6 – RELATED PARTY TRANSACTIONS On March 31 2015 $150,000 March 31, 2019, no On January 21, 2016, $35,000 rom a consultant to the company. The note is due in 2019 no $35,000. On August 6, 2017 second $119,713. one no

Note 7 - Income Taxes

Note 7 - Income Taxes	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 7 – INCOME TAXES Our NOL will begin to expire in 2027 382. 382. We file income tax returns in the U.S. and in the state of California with varying statutes of limitations. Our policy is to recognize interest expense and penalties related to income tax matters as a component of our provision for income taxes. There were no June 30, 2013. no not no no Net deferred tax assets consist of the following components as of: December 31, December 31, 2016 2015 Deferred tax assets: NOL carryover $ 274,526 $ 145,914 Valuation allowance (274,526 ) (145,914 ) Net deferred tax asset $ - $ - The income tax provision is summarized as follows: December 31, December 31, 2016 2015 Income tax benefit at statutory rate (35%) $ (96,084 ) $ (51,070 ) Valuation allowance 96,084 51,070 $ - $ - At December 31, 2016, $274 may 2027. No December 31, 2016 2015 We believe that our income tax filing positions and deductions will be sustained on audit and do not . Therefore, no 740. .

Note 8 - Subsequent Events

Note 8 - Subsequent Events	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 8 – SUBSEQUENT EVENTS On September 8th, 2017, ’s issued and outstanding shares by written consent in lieu of a meeting, filed a Certificate of Change (the “ Certificate of Change ”) with the Secretary of State of Delaware. As a result of the Certificate of Change, the Company will be changing its name to “Hoverink Biotechnologies, Inc.” , effective as of September 11, 2017.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10Q X. not not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company considers highly liquid financial instruments purchased with a maturity of three September 30, 2017 December 31, 2016 2015, no From time to time, we may $250,000 no not not
Segment Reporting, Policy [Policy Text Block]	Segmented Reporting FASB ASC 280,
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss “Reporting Comprehensive Income,” establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at September 30, 2017, no not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates and Assumptions In preparing financial statements in conformity with generally accepted accounting principles in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheet and revenue and expenses in the statement of operations. The accounting estimates that require our significant, difficult, and subjective judgments include: ● the assessment of recoverability of long lived assets; ● the valuation of derivative instruments; and ● the valuation and recognition of share-based compensation. Actual results may may
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company follows guidance for accounting for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements on a recurring basis. Additionally, the Company adopted guidance for fair value measurement related to nonfinancial items that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis. The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 three • Level I inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2 • Level 3 The level in the fair value hierarchy within which a fair measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety.
Development Stage Enterprise, Policy [Policy Text Block]	Development Stage Company The Company is a development stage company, as defined in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915. ’s planned principal operations have not Management plans to seek funding from its shareholders and other qualified investors to pursue its business plan.
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition According to ASC 605,
Advertising Costs, Policy [Policy Text Block]	Advertising We expense advertising costs as incurred. During the Year ended December 31, 2016 2015 no no
Earnings Per Share, Policy [Policy Text Block]	Loss per Common Share The basic earnings (loss) per share is calculated by dividing the Company ’s net income available to common shareholders by the weighted average number of common shares during the period. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items in the Company.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company utilizes the asset and liability method of accounting for income taxes. The asset and liability method requires that the current or deferred tax consequences of all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not not In July 2006, not fifty no December 31 2016 2015 September 30, 2017. The Company follows the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax balances and tax loss carry- forwards. Deferred tax assets and liabilities are measured using enacted or substantially enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment or substantive enactment.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-based Compensation The Company follows ASC 718 10, 718 10 No. 123, No. 25, 718 10 in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized. The Company has not not September 30, 2017 not nor no
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk The Company maintains its cash with a major financial institution located in the United States of America which it believes to be credit worthy. Balances are insured by the Federal Deposit Insurance Corporation up to $250,000.
Risks and Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties The Company has a limited operating history and has not In addition, the Company will compete with many companies that currently have extensive and well-funded projects, marketing and sales operations as well as extensive human capital. Our company may may
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In June 2014, 2014 10, 915 2014 10 2014 10 December 15, 2014, 2014 10 September 30, 2014, no 915. The FASB issued ASU 2014 15 August 27, 2014, statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one December 15, 2016, In November 2014, 2014 16, 815 2014 16 December 15, 2015. No. 2014 16 In August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 first 2018. 2016 15 not 2016 15 In May 2017, 2017 09, Compensation - Stock Compensation (Topic 718 718. 2017 09 June 30, 2019 not The Company has implemented all new accounting pronouncements that are in effect and that may not

Note 7 - Income Taxes (Tables)

Note 7 - Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, December 31, 2016 2015 Deferred tax assets: NOL carryover $ 274,526 $ 145,914 Valuation allowance (274,526 ) (145,914 ) Net deferred tax asset $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	December 31, December 31, 2016 2015 Income tax benefit at statutory rate (35%) $ (96,084 ) $ (51,070 ) Valuation allowance 96,084 51,070 $ - $ -

Note 1 - Nature of Operations16

Note 1 - Nature of Operations and Basis of Presentation (Details Textual) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Retained Earnings (Accumulated Deficit)	$ (410,381)	$ (274,526)	$ (145,914)
Funds Required for Future Operations	$ 10,000,000

Note 2 - Summary of Significa17

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash and Cash Equivalents, at Carrying Value	$ 0	$ 0	$ 0
Marketing and Advertising Expense		$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0
Allocated Share-based Compensation Expense	$ 0

Note 4 - Notes Payable - Rela18

Note 4 - Notes Payable - Related Party (Details Textual) - USD ($) xbrli-pure in Thousands	Aug. 11, 2017	Jan. 21, 2016	Jan. 04, 2015	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Notes Payable, Related Parties, Current				$ 154,653	$ 154,653	$ 120,214
Notes Payable, Related Parties, Noncurrent				115,060
Director [Member]
Related Party Transaction, Amounts of Transaction	$ 115,000		$ 150,000
Related Party Transaction, Rate	0.00%		0.00%
Notes Payable, Related Parties, Current				119,653
Notes Payable, Related Parties, Noncurrent				115,000
Consultant [Member]
Related Party Transaction, Amounts of Transaction		$ 35,000
Related Party Transaction, Rate		0.00%
Notes Payable, Related Parties, Current				$ 35,000

Note 5 - Capital Stock (Details

Note 5 - Capital Stock (Details Textual) - USD ($)	Sep. 22, 2017	Sep. 02, 2017	Feb. 16, 2015	Feb. 15, 2015	Dec. 31, 2015	Sep. 30, 2017	Dec. 31, 2016
Common Stock, Shares Authorized					100,000,000	100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share					$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized						0
Stock Redeemed or Called During Period, Shares				19,500,000
Common Stock, Redemption Price Per Share				$ 0.0001
Stock Redeemed or Called During Period, Value				$ 1,950
Stock Issued During Period, Shares, New Issues			13,372,000
Stock Issued During Period, Shares, Issued for Services	21,900,000	1,000,000

Note 6 - Related Party Transa20

Note 6 - Related Party Transactions (Details Textual) - USD ($) xbrli-pure in Thousands	Aug. 06, 2017	Jan. 21, 2016	Mar. 31, 2015	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Notes Payable, Related Parties, Current				$ 154,653	$ 154,653	$ 120,214
Vice President [Member]
Related Party Transaction, Amounts of Transaction	$ 119,713		$ 150,000
Related Party Transaction, Rate	0.00%		0.00%
Related Party Transaction, Term	1 year
Consultant [Member]
Related Party Transaction, Amounts of Transaction		$ 35,000
Related Party Transaction, Rate		0.00%
Notes Payable, Related Parties, Current				$ 35,000

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2013
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	$ 0	$ 0	$ 0	$ 0
Unrecognized Tax Benefits	0	0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	$ 0	0	0
Operating Loss Carryforwards		274
Income Tax Expense (Benefit)		$ 0	$ 0

Note 7 - Income Taxes - Net Def

Note 7 - Income Taxes - Net Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
NOL carryover	$ 274,526	$ 145,914
Valuation allowance	(274,526)	(145,914)
Net deferred tax asset

Note 7 - Income Taxes - Income

Note 7 - Income Taxes - Income Tax Provision (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income tax benefit at statutory rate (35%)	$ (96,084)	$ (51,070)
Valuation allowance	96,084	51,070
	$ 0	$ 0

Note 7 - Income Taxes - Incom24

Note 7 - Income Taxes - Income Tax Provision (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income tax benefit at statutory rate, percentage	35.00%	35.00%